TECHWIRE 30
(CIX: WRAL30)  1,102.96  up arrow+11.29  (1.03 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NQ: Apple)  108.00  up arrow+1.02  (0.95 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NY: QUINTILES)  58.54  up arrow+2.24  (3.98 %)  Updated: 04:15 PM EDT, Oct 31 2014
(OP: BASF SE)  88.22  up arrow+1.3  (1.5 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NQ: BioCryst)  11.72  down arrow-0.34  (-2.82 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NQ: BioDelivery)  17.40  down arrow-0.39  (-2.19 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NQ: CEMP)  13.60  down arrow-0.09  (-0.66 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NQ: Cisco Systems)  24.47  up arrow+0.39  (1.62 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NQ: Cree)  31.48  down arrow-0.03  (-0.1 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NQ: DARA)  0.85  down arrow-0.03  (-3.3 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NY: EMC CORPORATION)  28.73  up arrow+0.27  (0.95 %)  Updated: 04:15 PM EDT, Oct 31 2014
(NQ: Extreme Networks)  3.59  up arrow+0.06  (1.7 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NQ: FB)  74.99  up arrow+0.88  (1.19 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NY: GLAXOSMITHKLINE)  45.49  up arrow+0.35  (0.78 %)  Updated: 04:15 PM EDT, Oct 31 2014
(NQ: GOOG)  559.08  up arrow+8.77  (1.59 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NY: IBM)  164.40  up arrow+0.05  (0.03 %)  Updated: 04:15 PM EDT, Oct 31 2014
(NY: LH)  109.29  up arrow+1.9  (1.77 %)  Updated: 04:15 PM EDT, Oct 31 2014
(OP: Lenovo Group)  29.49  down arrow-0.07  (-0.24 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NY: MRK)  57.94  up arrow+0.63  (1.1 %)  Updated: 04:15 PM EDT, Oct 31 2014
(NQ: Microsoft Corp)  46.95  up arrow+0.9  (1.95 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NQ: NTAP)  42.80  up arrow+0.69  (1.64 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NY: NOVARTIS AG)  92.69  up arrow+0.74  (0.8 %)  Updated: 04:15 PM EDT, Oct 31 2014
(OP: Novozymes A/S)  46.30  down arrow-0.01  (-0.02 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NY: PFIZER)  29.95  up arrow+0.11  (0.37 %)  Updated: 04:15 PM EDT, Oct 31 2014
(NQ: Pozen)  9.07  down arrow-0.1  (-1.09 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NY: RED HAT)  58.92  up arrow+0.67  (1.15 %)  Updated: 04:15 PM EDT, Oct 31 2014
(NQ: BBRY)  10.50  up arrow+0.02  (0.19 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NQ: Salix)  143.85  down arrow-0.65  (-0.45 %)  Updated: 05:20 PM EDT, Oct 31 2014
(NQ: SQI)  14.91  down arrow-2.02  (-11.93 %)  Updated: 05:20 PM EDT, Oct 31 2014

Posts tagged “Targacept ”

Updated February 13

Premium Lock AstraZeneca returns pre-clinical compounds to Targacept

Targacept's collaboration with drug giant AstraZeneca has borne little fruit so far and the number of shots the partners have to come up with a winner is shrinking even more.

Targacept Targacept

November 5, 2013

Premium Lock Targacept's 3Q loss widens to $12.9M on higher R&D expenses

Targacept Targacept attributed the wider loss to a $3.9 million increase in R&D expenses. R&D spending in the quarter totaled $10.3 million, up from $6.4 million in the third quarter of 2012, as the company increased its spending for a phase 2b clinical study of TC-5214, an experimental treatment for overactive bladder.

August 6, 2013

Premium Lock Loss of AstraZeneca partnership swings Targacept to $12.4M 2Q loss

Targacept Although Targacept no longer brings in revenue from its AstraZeneca partnership, the company is expecting to report initial clinical trial results for three compounds in the next year.

Updated April 22, 2013

Premium Lock Targacept's schizophrenia treatment reaches important trial milestone

Targacept The Winston-Salem based biopharmaceutical firm has completed recruitment of patients for the Phase 2b study of its schizophrenia treatment

Updated March 18, 2013

Premium Lock  Targacept's top business executive to depart company

Targacept Targacept's (NASDAQ:TRGT) top business executive, who succeeded in landing potentially lucrative deals with big pharmas GlaxoSmithKline and AstraZeneca only to see those partnerships fail to yield any successful drugs, is leaving.

Updated March 6, 2013

Premium Lock Targacept, AstraZeneca restructure drug development pact

Targacept Targacept is regaining all rights to an Alzheimer's disease drug candidate in mid-stage clinical trials and the company will have additional flexibility pursuing development of other compounds included in a newly restructured agreement with drug partner AstraZeneca.

November 15, 2012

Premium Lock Targacept hires former Solvay exec as its new CEO

Targacept Targacept, which recently has laid off much of its staff and cut back on drug development, has hired former Solvay executive Stephen Hill as its new chief executive officer.

October 8, 2012

Premium Lock Targacept to cut 38% of its work force, close labs

Layoffs       The Winston-Salem based drug development firm says it will lay off another 28 workers and reduce operations in wake of recent product candidate failure.

September 17, 2012

Premium Lock Targacept to make more layoffs after drug candidate fails

Layoffs       The Winston-Salem drug firm plans to make more layoffs after the failure of a drug the company was testing as a possible treatment for ADHDi, or ttention deficit/hyperactivity disorder.

September 5, 2012

Premium Lock Targacept pursues treatment for overactive bladder

The Winston-Salem-based company announced plans on Wednesday to pursue the development of TC-5214 as a treatment for overactive bladder (OAB).

Targacept Targacept

June 4, 2012

Premium Lock Setbacks precede resignation of Targacept co-founder

Targacept's HQ Don deBethizy is stepping down as CEO and chairman of the drug development company. DeBethizy said he "decided to step down for personal considerations." But the move follows some setbacks for the company, most prominent the phase 3 failure of the company's lead drug, a depression treatment.

June 4, 2012

Premium Lock Targacept CEO resigns, also leaves firm's board

Targacept CEO J. Donald deBethizy Don deBethizy is leaving the Winston-Salem based drug firm. Recent drug candidate failures have pummled the company.

May 4, 2012

Premium Lock Targacept cuts mean focus on existing drug candidates

CEO Don deBethizy says the Winston-Salem based drug firm doesn't plan to advance new preclinical drug candidates in the near term "until we restore the shareholder value."

Targacept's HQ Targacept's HQ

May 4, 2012

Premium Lock Earnings reports: SciQuest, PowerSecure, Furiex, Targacept

Earnings    Profits for SciQuest, Targacept; in the red for PowerSecure, Furiex.

May 3, 2012

Premium Lock In wake of drug failure, Targacept to realign resources

Targacept Targacept must now realign its resources to focus on its other programs, including an experimental Alzheimer's disease treatment that remains partnered with AstraZeneca.

April 26, 2012

Premium Lock Drug firm Targacept to slash 46% of work force

The Winston-Salem based firm is slashing its workforce by nearly half, part of a restructuring plan that comes one month after its lead drug candidate, a depression drug, failed the last of a series of phase 3 clinical trials.

Targacept's Headquarters Targacept's Headquarters

Updated April 12, 2012

Premium Lock Oops: Targacept lowers asthma drug candidate results

The Winston-Salem based firm last month released top-line phase 2 results for a compound that showed the it met both goals in the clinical trial. But Targacept now says the discovery of a "statistical analysis error" now shows they met just one of the two phase 2 endpoints.

Targacept Targacept

Updated March 27, 2012

Premium Lock Targacept drug candidate shows promise against asthma

Targacept However, a trial of the same compound to combat type 2 diabetes failed. The Winston-Salem based firm will drop its further develoment as a diabetes target.

Updated March 20, 2012

Premium Lock Targacept gears for changes after antidepressant drug candidate failure

Targacept's HQ Two clinical trials of a treatment for major depressive disorder result in failure of the proposed antidepressant.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Dr. Mike Walden
Tech economy
Frank Vinluan
Life science
Vivek Wadhwa
Commentary
Scroll